Narmac you are right this could be a complete failure as with most  Biotechs. There is a graveyard of dead ones. I happen to disagree. Not sure we are on the same side and I don't care whatever your position is and that is what makes the market work. Nevertheless don't want to argue semantics on it. No matter what it won't matter what we think. We shall see. I do believe if they don't make progress on the revenue stream this year it may just be Hasta la vista. But not yet! GLTA.